清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

鲁索利替尼 骨髓纤维化 Janus激酶抑制剂 安慰剂 医学 贾纳斯激酶 临床试验 Janus激酶2 内科学 双盲 肿瘤科 病理 替代医学 骨髓 受体
作者
Srđan Verstovšek,Ruben A. Mesa,Jason R. Gotlib,Richard S. Levy,Vikas K Gupta,John F. DiPersio,John Vincent Catalano,Michael W. Deininger,Carole Brennan Miller,Richard T. Silver,Moshe Talpaz,Elliott F. Winton,Jimmie Huling Harvey,Murat O. Arcasoy,Elizabeth Olson Hexner,Roger M. Lyons,RONALD L. PAQUETTE,Azra Raza,Kris Vaddi,Susan Erickson‐Viitanen
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:366 (9): 799-807 被引量:2245
标识
DOI:10.1056/nejmoa1110557
摘要

BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS: In this double-blind trial, we randomly assigned patients with intermediate-2 or high-risk myelofibrosis to twice-daily oral ruxolitinib (155 patients) or placebo (154 patients). The primary end point was the proportion of patients with a reduction in spleen volume of 35% or more at 24 weeks, assessed by means of magnetic resonance imaging. Secondary end points included the durability of response, changes in symptom burden (assessed by the total symptom score), and overall survival. RESULTS: The primary end point was reached in 41.9% of patients in the ruxolitinib group as compared with 0.7% in the placebo group (P<0.001). A reduction in spleen volume was maintained in patients who received ruxolitinib; 67.0% of the patients with a response had the response for 48 weeks or more. There was an improvement of 50% or more in the total symptom score at 24 weeks in 45.9% of patients who received ruxolitinib as compared with 5.3% of patients who received placebo (P<0.001). Thirteen deaths occurred in the ruxolitinib group as compared with 24 deaths in the placebo group (hazard ratio, 0.50; 95% confidence interval, 0.25 to 0.98; P=0.04). The rate of discontinuation of the study drug because of adverse events was 11.0% in the ruxolitinib group and 10.6% in the placebo group. Among patients who received ruxolitinib, anemia and thrombocytopenia were the most common adverse events, but they rarely led to discontinuation of the drug (in one patient for each event). Two patients had transformation to acute myeloid leukemia; both were in the ruxolitinib group. CONCLUSIONS: Ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. These benefits came at the cost of more frequent anemia and thrombocytopenia in the early part of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, NCT00952289.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chemlink完成签到 ,获得积分10
2秒前
2秒前
嘿嘿完成签到 ,获得积分10
3秒前
lamb完成签到 ,获得积分10
3秒前
yuanmeng434完成签到 ,获得积分10
4秒前
wei发布了新的文献求助10
5秒前
Yuna发布了新的文献求助10
6秒前
清爽水之完成签到,获得积分10
12秒前
贪玩鸣凤完成签到,获得积分10
33秒前
哈哈哈哈完成签到 ,获得积分10
35秒前
孝顺的丹烟完成签到,获得积分10
43秒前
43秒前
王誉霖发布了新的文献求助10
45秒前
50秒前
楚楚完成签到 ,获得积分10
52秒前
54秒前
王誉霖完成签到,获得积分10
55秒前
大方定帮完成签到,获得积分10
1分钟前
合适乐巧完成签到 ,获得积分10
1分钟前
缓慢凛完成签到,获得积分10
1分钟前
ghost完成签到 ,获得积分10
1分钟前
稳重傲柔完成签到,获得积分10
1分钟前
万能图书馆的应助被边疆采纳,获得10
1分钟前
温柔的海秋完成签到,获得积分10
1分钟前
1分钟前
任性的千筹完成签到,获得积分10
1分钟前
边疆发布了新的文献求助10
1分钟前
单薄飞双完成签到,获得积分10
1分钟前
Jzhaoc580完成签到 ,获得积分10
1分钟前
边疆完成签到,获得积分10
2分钟前
2分钟前
麦子发布了新的文献求助10
2分钟前
李木禾完成签到 ,获得积分10
2分钟前
Hello的应助被麦子采纳,获得10
2分钟前
俭朴迎荷完成签到,获得积分10
2分钟前
2分钟前
今后的应助被catalyst326采纳,获得10
2分钟前
冥土追魂发布了新的文献求助10
2分钟前
震动的醉蓝完成签到,获得积分10
2分钟前
慕青的应助被冥土追魂采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166463
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750516
捐赠科研通 7757246
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553507
邀请新用户注册赠送积分活动 2473845